Cargando…
Asymptomatic Crohn’s disease identified in a patient being treated with secukinumab: A case report
IL-17 antagonism is among the most potent treatments for psoriasis. Generally safe, new onset and exacerbations of inflammatory bowel disease may occur in association with IL-17 therapy. We describe a patient with long-standing history of psoriasis and psoriatic arthritis in whom asymptomatic Crohn’...
Autores principales: | Haidari, Wasim, Al-Naqshabandi, Sarah, Ahn, Christine S, Bloomfeld, Richard S, Feldman, Steven R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900620/ https://www.ncbi.nlm.nih.gov/pubmed/31839950 http://dx.doi.org/10.1177/2050313X19893580 |
Ejemplares similares
-
Pyoderma gangrenosum treated with secukinumab: A case report
por: McPhie, Meghan L, et al.
Publicado: (2020) -
Dyshidrotic eczema in two patients on secukinumab for plaque
psoriasis: A case report
por: Bose, Reetesh, et al.
Publicado: (2020) -
A case report of disseminated verrucosis secondary to ustekinumab in
a patient with Crohn’s disease
por: Svoboda, Steven A, et al.
Publicado: (2021) -
Sweet’s syndrome and fistulizing Crohn’s disease: A case report
por: Siedlikowski, Stefan T, et al.
Publicado: (2019) -
Vulvar swelling and the timely diagnosis of Crohn’s disease: A case report
por: Gomolin, Arieh, et al.
Publicado: (2021)